Aconcagua Bio's ACCG-2671 obesity trial recruiting under Structure Therapeutics subsidiary
A first-in-human trial of the oral amylin/calcitonin agonist ACCG-2671 is recruiting, with the study registered on September 11, 2026.
This week brought one registry update tied to Structure Therapeutics.
- ACCG-2671, described as a nonpeptide dual amylin and calcitonin receptor agonist (DACRA)1, is being tested in a Phase 1/2 study that is recruiting, sponsored by Aconcagua Bio, Inc., which the registry describes as a wholly owned subsidiary of Structure Therapeutics1. The trial began on an actual start date of 2025-12-29 and plans to enroll 164 participants, evaluating single and multiple ascending doses as well as a food effect assessment, with Part 3 (Multiple Ascending Dose) conducted in otherwise healthy participants with obesity (BMI ≥ 30 kg/m2) for 84 days1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.